Compare KE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KE | PRTA |
|---|---|---|
| Founded | 1961 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.3M | 472.1M |
| IPO Year | N/A | N/A |
| Metric | KE | PRTA |
|---|---|---|
| Price | $29.46 | $11.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $28.00 | $18.86 |
| AVG Volume (30 Days) | 149.0K | ★ 603.3K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.88 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $1,478,074,000.00 | $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.71 | $819.08 |
| P/E Ratio | $30.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.41 | $4.32 |
| 52 Week High | $33.19 | $17.66 |
| Indicator | KE | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 59.50 |
| Support Level | $28.24 | $10.14 |
| Resistance Level | $29.93 | $11.57 |
| Average True Range (ATR) | 0.95 | 0.57 |
| MACD | 0.23 | 0.06 |
| Stochastic Oscillator | 87.43 | 71.70 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.